| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
DNA polymerases (enzymes involved in DNA replication and repair). The compound acts as a nucleoside analog, incorporating into DNA and terminating chain elongation.
|
|---|---|
| ln Vitro |
In cell-free assays, 2'-Deoxy-2‘-fluoroarabinoadenosine is a substrate for cellular kinases that convert it into its active triphosphate form. The triphosphate then acts as a chain terminator for DNA polymerases, including HIV reverse transcriptase. The specific IC₅0 for inhibition of HIV‑1 reverse transcriptase is not provided in the available data.
|
| ln Vivo |
In vitro, 2'-Deoxy-2‘-fluoroarabinoadenosine inhibits the proliferation of various cancer cell lines by inducing DNA chain termination during replication, leading to cell cycle arrest and apoptosis. It also exhibits antiviral activity against HIV, as it can be incorporated into viral DNA by reverse transcriptase, leading to premature chain termination.
|
| Enzyme Assay |
A general cell‑free protocol for assessing nucleoside analog activity: The compound is incubated with cellular lysates containing thymidine kinase or other nucleoside kinases to measure phosphorylation to the monophosphate form. For DNA polymerase inhibition, the 5'‑triphosphate derivative is synthesized, and a primer extension assay is performed using a DNA primer/template, the triphosphate, and purified DNA polymerase (e.g., HIV‑1 reverse transcriptase or human DNA polymerase alpha). The reaction products are analyzed by denaturing PAGE to determine the extent of chain termination. The IC₅0 is calculated.
|
| Cell Assay |
A general cellular protocol for assessing anti‑HIV activity: HIV‑1‑infected MT‑2 cells (or other susceptible cell lines) are cultured in 96‑well plates. The cells are treated with serial dilutions of 2‘-Deoxy-2'-fluoroarabinoadenosine (0.01 nM to 100 uM) for 5‑7 days. The supernatant is collected, and HIV‑1 p24 antigen levels are measured by ELISA to determine the antiviral EC₅0. Cytotoxicity is assessed in uninfected cells using the MTT assay to calculate the CC₅0. The selectivity index (SI = CC₅0/EC₅0) is calculated.
|
| Animal Protocol |
A general animal protocol for evaluating anticancer activity: Nude mice are subcutaneously implanted with human tumor xenografts (e.g., A549 lung cancer or HCT116 colon cancer cells). When tumors reach ~150 mm3, the mice are randomized (n=8/group). 2‘-Deoxy-2'-fluoroarabinoadenosine is administered intraperitoneally (IP) at doses of 10, 30, and 100 mg/kg once daily for 14‑21 days. Tumor volume is measured twice weekly. At study end, tumors are harvested for histological analysis and assessment of apoptosis (TUNEL). For HIV studies, the compound is evaluated in a Hu‑PBMC‑SCID mouse model of HIV‑1 infection.
|
| ADME/Pharmacokinetics |
General pharmacokinetic protocol for 2‘-Deoxy-2'-fluoroarabinoadenosine: Male Sprague‑Dawley rats are administered the compound via oral gavage (PO, 10 mg/kg) and intravenous (IV, 2 mg/kg). Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours. Plasma concentrations are quantified by LC‑MS/MS. PK parameters (Cmax, Tmax, AUC, t½, clearance, Vd, and oral bioavailability) are calculated. As a nucleoside analog, the compound is expected to be rapidly distributed and cleared, primarily via renal excretion.
|
| Toxicity/Toxicokinetics |
General toxicity protocol for 2‘-Deoxy-2'-fluoroarabinoadenosine: A 28‑day repeat‑dose IV toxicity study is performed in rats at doses of 5, 15, and 50 mg/kg/day. Parameters include clinical signs, body weight, food consumption, hematology (with special attention to platelet, RBC, WBC counts), serum chemistry (ALT, AST, BUN, creatinine, uric acid), and histopathology of bone marrow, gastrointestinal tract, and kidneys. The primary dose‑limiting toxicities of nucleoside analogs are typically myelosuppression (anemia, neutropenia) and gastrointestinal toxicity.
|
| References | |
| Additional Infomation |
2‘-Deoxy-2'-fluoroarabinoadenosine has the molecular formula C10H12FN₅O3 and a molecular weight of 269.23 g/mol. The compound is a purine nucleoside analog that inhibits DNA synthesis by acting as a chain terminator. The fluorine at the 2‘ position of the arabinose sugar confers metabolic stability by preventing cleavage of the glycosidic bond. It has been investigated for anticancer activity against various solid tumors and for antiviral activity against HIV.
|
| Molecular Formula |
C10H12FN5O3
|
|---|---|
| Molecular Weight |
269.23
|
| Exact Mass |
269.092
|
| CAS # |
20227-41-2
|
| PubChem CID |
11065470
|
| Appearance |
Solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
628.6±65.0 °C at 760 mmHg
|
| Flash Point |
334.0±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.834
|
| LogP |
-0.32
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
F[C@@]1([H])[C@@]([H])([C@@]([H])(C([H])([H])O[H])O[C@@]1([H])N1C([H])=NC2=C(N([H])[H])N=C([H])N=C12)O[H]
|
| InChi Key |
ZGYYPTJWJBEXBC-GQTRHBFLSA-N
|
| InChi Code |
InChI=1S/C10H12FN5O3/c11-5-7(18)4(1-17)19-10(5)16-3-15-6-8(12)13-2-14-9(6)16/h2-5,7,10,17-18H,1H2,(H2,12,13,14)/t4-,5+,7-,10-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7143 mL | 18.5715 mL | 37.1430 mL | |
| 5 mM | 0.7429 mL | 3.7143 mL | 7.4286 mL | |
| 10 mM | 0.3714 mL | 1.8571 mL | 3.7143 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
